WASHINGTON - The Food and Drug Administration announced Wednesday that it plans to streamline the approval process for cheaper, "biosimilar" alternatives to biologic drugs in an effort to reduce ...

On October 29, 2025, the U.S. Food and Drug Administration (FDA), in coordination with the Department of Health and Human Services (HHS) and ...

In a promising move to tackle the escalating costs of prescription drugs, a new initiative known as the Limited-Competition Generic Market Priority Review Voucher (LCGM PRV) Program is making waves.

It's the Trump administration's latest move to rein in high prescription drug costs in the U.S., and could be a blow to pharmaceutical companies.

The FDA's push for lower-cost medicines looks good on paper, but the patent office under President Trump may be going in the ...

U.S. regulators approved dozens of inhalers to treat asthma and chronic obstructive pulmonary disease over a recent 15-year period, but a new study found that generic companies have only twice ...

Drug development pipelines are the lifeblood of the pharmaceutical industry. It is crucial for investors to understand milestones like FDA approvals and the impact of losing exclusivity on profits to ...

See how Teva Pharmaceutical Industries Limited's growth strategy and focus on specialty medicines are driving a turnaround.

Healthcare incentives, price transparency, patent length, and the interaction between medical needs and regulatory processes all need to be re-examined. While there is lots of disagreement, the ...